Shawn Tomasello Acquires 50,000 Shares of 4D Molecular Therapeutics

Shawn Tomasello made a notable move on June 17, 2026, by purchasing 50,000 shares of 4D Molecular Therapeutics, Inc. (NasdaqGS: FDMT). This transaction did not involve a planned insider trading plan and reflects Tomasello's interest in the biotechnology company.

Insider Buying and Selling at 4D Molecular Therapeutics, Inc.

Alongside Shawn Tomasello, several other insiders also bought shares of 4D Molecular Therapeutics on the same day. Charles Theuer, Glenn Sblendorio, Susannah Gray, Jacob Chacko, and Nancy Miller-Rich each acquired 50,000 shares, while John Milligan purchased 75,000 shares. These acquisitions were not part of any prearranged trading plans.

Other Institutional Activity in 4D Molecular Therapeutics

Institutional investors have been active in 4D Molecular Therapeutics. Janus Henderson Group PLC increased its holdings by 611,276 shares, bringing its total to 5,247,151 shares worth about $48.9 million. RA Capital Management, L.P. reduced its position by 603,432 shares, now holding 5,049,779 shares valued at approximately $47 million. Goldman Sachs Group Inc. trimmed its stake by 97,467 shares, resulting in 4,205,438 shares valued at $39.2 million. BlackRock, Inc. added 80,427 shares, ending with 4,145,303 shares worth around $38.6 million.

4D Molecular Therapeutics Stock Snapshot

Shares of 4D Molecular Therapeutics traded near $9.42. The company has a market cap of roughly $505 million and a beta of 2.756, indicating high volatility compared to the market. The stock's 52-week range is between $3.68 and $12.34. Its 50-day moving average is $9.43, with a 200-day moving average of $9.24. The company's current ratio stands at 9.339, and its quick ratio is 9.006, reflecting strong liquidity.

Recent Earnings

In its latest earnings report, 4D Molecular Therapeutics posted revenue of $88.2 million, representing a growth of 216.6%. Despite the impressive revenue growth, the company remains unprofitable with a negative net margin of 182.3% and a return on equity of -34.9%. The company is set to announce its next earnings on August 10, 2026.

Analysts Set New Price Targets

Analysts remain optimistic about 4D Molecular Therapeutics. On March 30, 2026, Jefferies assumed coverage with a buy rating and a $21 price target. HC Wainwright & Co. reiterated its buy rating with a $36 target on March 20, 2026. RBC Capital maintained its buy rating, setting a $35 target on March 19, 2026, while Chardan Capital also maintained a buy rating with a $26 target on the same day. The consensus among nine analysts is a buy recommendation, with a mean price target of $28.22.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. is a biotechnology company based in Emeryville, California. It focuses on developing adeno-associated virus vectors through its proprietary platform, Therapeutic Vector Evolution. The company is working on treatments for retinal vascular diseases, cystic fibrosis, geographic atrophy, and alpha-1 anti-trypsin deficiency lung disease. Founded in 2013, the company collaborates with Otsuka Pharmaceutical Co., Ltd. and is led by CEO Dr. David H. Kirn.

Bottom Line

Shawn Tomasello's purchase of 50,000 shares of 4D Molecular Therapeutics adds to the recent insider buying activity. The stock, trading around $9.42, shows a significant interest from institutional investors and analysts who maintain a positive outlook. Investors should note that while this insider activity is noteworthy, it does not necessarily indicate future performance, as insider transactions are just one piece of the investment puzzle.